Baidu
map

JAMA Oncol:定期低剂量服用阿司匹林真的可降低民众患结直肠癌风险

2016-03-04 MedSci MedSci原创

背景美国预防医学会建议美国成人服用阿司匹林预防结直肠癌和心血管疾病。然而,使用阿司匹林与民众患癌风险和潜在的副作用之间的关系尚不清楚。 目的该研究的目的是探究服用阿司匹林的潜在好处及对特定癌症的预防作用。研究人员通过两项美国大型前瞻性群组研究即护士健康研究(1980-2010)和医务人员随访研究(1986-2012),对135965名医务人员(88084名女性和47881名男性)进行了随访,每2年

背景

美国预防医学会建议美国成人服用阿司匹林预防结直肠癌和心血管疾病。然而,使用阿司匹林与民众患癌风险和潜在的副作用之间的关系尚不清楚。

目的

该研究的目的是探究服用阿司匹林的潜在好处及对特定癌症的预防作用。

研究人员通过两项美国大型前瞻性群组研究即护士健康研究(1980-2010)和医务人员随访研究(1986-2012),对135965名医务人员(88084名女性和47881名男性)进行了随访,每2年收集一次他们服用阿司匹林的信息。研究人员于1976年招募了女性参与者(年龄为30-55岁),并在1986年招募了男性参与者(年龄为40-75岁)。护士健康研究中研究人员最后一次随访时间是2012年6月60日。医务人员随访研究中研究人员最后一次随访时间是2010年1月31日,并与2014年9月15日-2015年12月17日整理数据。研究人员关注的主要结果是民众患某些癌症的相对风险(RRs)和人群归因风险(PAR)。

结果

一共有88084名女性和47881名男性接受长达32年的随访。期间共有20414名女性癌症患者和7571名男性癌症患者。与不定时服用相比,定期服用阿斯匹林的民众患癌症的总体风险较低(RR:0.97;95%CI:0.94-0.99),这主要是由于胃肠道肿瘤的发生率较低(RR:0.85;95%CI:0.85-0.80),特别是结直肠肿瘤(RR:0.81;95%CI:0.81-0.75)。每周规律服用阿司匹林0.5-1.5片对预防胃肠道肿瘤由明显效果,最短坚持时间需为6年。对于50岁以上的民众而言,规律服用阿司匹林可以预防结直肠肿瘤的发生(不进行胃肠镜检查的民众:33/100000个人年,PAR:17.0%;进行胃肠镜检查的民众:18100000个人年,PAR:8.5%)。规律服用阿司匹林并不会降低民众患乳腺癌、侵袭性前列腺癌或肺癌的风险。


结论

长期规律服用阿司匹林会降低民众总体的患癌风险,尤其是显著降低民众患胃肠道肿瘤的风险。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705327, encodeId=d03a1e05327be, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Aug 14 06:15:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061517, encodeId=86d9206151e7e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 01 12:15:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864759, encodeId=b9391864e59f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 05 09:15:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68112, encodeId=9bd56811202, content=吃起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Mar 07 21:12:00 CST 2016, time=2016-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452789, encodeId=503e1452e89fa, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480424, encodeId=4f1f1480424c6, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705327, encodeId=d03a1e05327be, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Aug 14 06:15:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061517, encodeId=86d9206151e7e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 01 12:15:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864759, encodeId=b9391864e59f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 05 09:15:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68112, encodeId=9bd56811202, content=吃起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Mar 07 21:12:00 CST 2016, time=2016-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452789, encodeId=503e1452e89fa, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480424, encodeId=4f1f1480424c6, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=)]
    2016-05-01 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1705327, encodeId=d03a1e05327be, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Aug 14 06:15:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061517, encodeId=86d9206151e7e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 01 12:15:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864759, encodeId=b9391864e59f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 05 09:15:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68112, encodeId=9bd56811202, content=吃起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Mar 07 21:12:00 CST 2016, time=2016-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452789, encodeId=503e1452e89fa, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480424, encodeId=4f1f1480424c6, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=)]
    2016-12-05 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705327, encodeId=d03a1e05327be, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Aug 14 06:15:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061517, encodeId=86d9206151e7e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 01 12:15:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864759, encodeId=b9391864e59f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 05 09:15:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68112, encodeId=9bd56811202, content=吃起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Mar 07 21:12:00 CST 2016, time=2016-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452789, encodeId=503e1452e89fa, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480424, encodeId=4f1f1480424c6, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=)]
    2016-03-07 jetleo

    吃起来

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1705327, encodeId=d03a1e05327be, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Aug 14 06:15:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061517, encodeId=86d9206151e7e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 01 12:15:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864759, encodeId=b9391864e59f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 05 09:15:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68112, encodeId=9bd56811202, content=吃起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Mar 07 21:12:00 CST 2016, time=2016-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452789, encodeId=503e1452e89fa, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480424, encodeId=4f1f1480424c6, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1705327, encodeId=d03a1e05327be, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Aug 14 06:15:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061517, encodeId=86d9206151e7e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 01 12:15:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864759, encodeId=b9391864e59f2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 05 09:15:00 CST 2016, time=2016-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68112, encodeId=9bd56811202, content=吃起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Mon Mar 07 21:12:00 CST 2016, time=2016-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452789, encodeId=503e1452e89fa, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480424, encodeId=4f1f1480424c6, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sun Mar 06 11:15:00 CST 2016, time=2016-03-06, status=1, ipAttribution=)]

相关资讯

纯干货:哪些人群需要使用小剂量阿司匹林?

(一)用于缺血性心血管病高危人群一级预防的建议   建议下列高危人群应用阿司匹林(75~100 mg/d)进行一级预防: 1.患有高血压但血压控制满意(<150/90mmHg),同时有下列情况之一者: ①年龄在50岁以上。 ②具有靶器官损害,包括血浆肌酐中度增高。 ③糖尿病。 2. 患有2型糖尿病,40岁以上,同时有心血管危险因素者:

Stroke:正在服用阿司匹林的患者发生缺血性卒中该怎样抗血小板治疗?

背景和目的:当服用阿司匹林时发生缺血性卒中,在不同的抗血小板策略中选择是一种常见的临床挑战,目前尚缺乏相关处理的数据。方法:这项研究是分析韩国14家医院的前瞻性的多中心卒中注册表数据库中的数据。招募急性非心源性卒中的患者,在卒中发生时正服用阿司匹林预防缺血性事件的发生。研究者根据随后的抗血小板治疗策略将其分为3组;维持阿司匹林单药治疗(MA组)、应用非阿司匹林抗血小板药物(SA组),添加另一种抗血

救命药硝酸甘油、复方丹参滴丸和阿司匹林该怎么用?

再次忠告50岁以上的爸爸妈妈们一定要记住:在睡眠时如果心脏病突发,剧烈胸疼足以把人从沉睡中痛醒,立刻口含十粒复方丹参滴丸,或者硝酸甘油片2片,或者阿司匹林3片(300mg)嚼服!接着立刻联络急救中心,然后坐在椅子或沙发上静候援助,千万别躺下!心脏科医师强调,如果每个看到这条微信的人,不要光点赞,能够转发10份给其他人,肯定至少有一条命将会被救回。 刚一降温,这条消息又出来了,您要转发

ASCO:定期服用阿司匹林或可降低个体因前列腺癌而导致的死亡

近日,在旧金山举办的美国临床肿瘤学会年会(ASCO)上,一项来自哈佛大学的最新研究显示,定期服用阿司匹林的男性或许因前列腺癌而死亡的风险会降低;研究人员表示,个体在诊断为前列腺癌后定期摄入阿司匹林可降低个体因前列腺癌死亡风险将近40%,而如果说阿司匹林可以预防致死性癌症或许为时尚早,但是因阿司匹林对心血管效应而获益的前列腺癌患者或许可以考虑定期服用阿司匹林。 由于这只是一个观察性的研究结果,没有

Gastroenterology:阿司匹林+骨化三醇+碳酸钙,能不能预防结直肠腺瘤的复发?

研究者进行了一项随机双盲的安慰剂对照试验,探究乙酰水杨酸(阿司匹林)、骨化三醇和碳酸钙能否预防结直肠腺瘤的复发。该研究纳入了2004-2010年间1107名结直肠散发性腺瘤性息肉切除患者,纳入符合以下标准的患者:1个息肉但直径>1cm;>1个息肉;一级亲属中有结直肠癌患者。将患者随机分为试验组(n = 209;0.5 μg骨化三醇+75 mg阿司匹林+1250 mg碳酸钙)和对照组(n = 218

NEJM:行冠状动脉手术前是否应停用阿司匹林药物?

以往的研究中发现,大多数的冠状动脉疾病患者都会服用阿司匹林预防心肌梗死和中风等。而服用阿司匹林对接受手术的患者有出血风险,对于在行冠状动脉手术前是否应该停止服用阿司匹林,目前人们尚未清楚。

Baidu
map
Baidu
map
Baidu
map